Cynata Financial Statements From 2010 to 2024
CYYNF Stock | USD 0.11 0.00 0.00% |
Check Cynata Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cynata main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Cynata financial statements analysis is a perfect complement when working with Cynata Therapeutics Valuation or Volatility modules.
Cynata |
Cynata Therapeutics Limited Company Operating Margin Analysis
Cynata Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Cynata Therapeutics Operating Margin | (0.78) % |
Most of Cynata Therapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cynata Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Competition |
Based on the recorded statements, Cynata Therapeutics Limited has an Operating Margin of -0.7809%. This is 97.77% lower than that of the Healthcare sector and 99.3% lower than that of the Biotechnology industry. The operating margin for all United States stocks is 85.83% lower than that of the firm.
Cynata Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cynata Therapeutics's current stock value. Our valuation model uses many indicators to compare Cynata Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cynata Therapeutics competition to find correlations between indicators driving Cynata Therapeutics's intrinsic value. More Info.Cynata Therapeutics Limited is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cynata Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cynata Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cynata Therapeutics' earnings, one of the primary drivers of an investment's value.About Cynata Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Cynata Therapeutics income statement, its balance sheet, and the statement of cash flows. Cynata Therapeutics investors use historical funamental indicators, such as Cynata Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cynata Therapeutics investors may use each financial statement separately, they are all related. The changes in Cynata Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cynata Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cynata Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cynata Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia. Cynata Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cynata Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cynata Therapeutics' short interest history, or implied volatility extrapolated from Cynata Therapeutics options trading.
Pair Trading with Cynata Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cynata Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cynata Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Cynata Pink Sheet
0.85 | YUMM | Yummies | PairCorr |
0.63 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
0.56 | REGN | Regeneron Pharmaceuticals Financial Report 2nd of May 2024 | PairCorr |
0.49 | AAGH | America Great Health | PairCorr |
0.46 | URYL | United Royale Holdings | PairCorr |
The ability to find closely correlated positions to Cynata Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cynata Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cynata Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cynata Therapeutics Limited to buy it.
The correlation of Cynata Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cynata Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cynata Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cynata Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Cynata Therapeutics Correlation against competitors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Cynata Pink Sheet analysis
When running Cynata Therapeutics' price analysis, check to measure Cynata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cynata Therapeutics is operating at the current time. Most of Cynata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cynata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cynata Therapeutics' price. Additionally, you may evaluate how the addition of Cynata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |